Mortality due to COVID-19 in a Patient with Severe Asthma Receiving Omalizumab Treatment: A Case Report

Cakmak M. E., Kaya S. B., Bostan Ö., Tuncay G., DAMADOĞLU E., KARAKAYA G., ...Daha Fazla

Asthma Allergy Immunology, cilt.18, ss.27-29, 2020 (ESCI, Scopus, TRDizin) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 18
  • Basım Tarihi: 2020
  • Doi Numarası: 10.21911/aai.584
  • Dergi Adı: Asthma Allergy Immunology
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.27-29
  • Anahtar Kelimeler: Anti-ige, Asthma, Covid-19, Omalizumab, Severe allergic asthma
  • Marmara Üniversitesi Adresli: Hayır

Özet

Coronavirus disease 2019 (COVID-19) originated in Wuhan, China, and caused a pandemic in the world. SARS-CoV-2 infections have a great health risk, especially in patients with chronic diseases. There are concerns that COVID-19 will be more severe in patients with severe asthma. The efficacy and safety of biological agents used in severe asthmatics during SARS-CoV-2 infections are currently unknown. In this case report, we present a patient who had been using omalizumab for five years with the diagnosis of severe asthma and died due to COVID-19. To the best of our knowledge, this is the first case of a Turkish patient who died due to COVID-19 under omalizumab treatment for severe asthma.